



壹、林口長庚醫院2025年二月份SCI頂尖論文榜

1、論文出版期間：2025/2/1~2025/2/28期間SCIE 資料庫所收錄的文獻(文章形式以「article」及「review」為主)。

※資料庫論文發表後，約需1個半至2個月的時間才會被SCI資料庫收錄。若論文已出版，但尚未被資料庫收錄之頂尖論文將公告於下期榜單中。

2、SCI 頂尖論文選錄標準：發表論文之投稿期刊為Journal Citation Reports (JCR)該學科主題依影響係數(Impact Factor)排名前**5%**，共**8**篇。

3、Journal Citation Report 之Impact Factor(簡稱IF)為**2023**年版。

4、本院以第一作者或指導作者發表之論文，皆以綠色底色標示，共**3**篇。

5、文章編號依刊名字母排列。

公告日期：2025年3月10日

項目	出處	期刊 IF值	百分比 排名	主題	篇名	作者及發表論文單位
1	ADVANCED MATERIALS Volume 37 Issue 5 Published FEB 2025	27.4	2.48%	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Hierarchically Promoted Light Harvesting and Management in Photothermal Solar Steam Generation	[Chang, Huan-Tsung] Dept Gen Surg, Div Breast Surg
2	ALZHEIMERS & DEMENTIA Volume 21 Issue 2 Published FEB 2025	13.1	2.36%	Clinical Neurology	Interocular retinal asymmetry and cognitive frailty: A prospective cohort study	[李泳松 ¹] Dept Ophthalmol

項目	出處	期刊 IF值	百分比 排名	主題	篇名	作者及發表論文單位
3	ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY Volume 65 Page 375-396 Published 2025	11.2	2.13%	Pharmacology & PharmacyToxicology	PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer	[王齡玉 ¹ ✉; Hsu, Hung-Chih] Division of Hematol Oncol [Lin, Kwang-Huei] Liver Res Ctr
4	BRITISH JOURNAL OF SURGERY Volume 112 Issue 2 Article Number znaf004 Published FEB 12 2025	8.7	2.83%	Surgery	Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: The prospective multicentre preSINO trial	[Gao, Xing; Chao, Yinkai] Div Thorac Surg
5	JOURNAL OF ADVANCED NURSING DOI 10.1111/jan.16802 Early Access FEB 2025	3.8	4.76%	Nursing	Empowerment and Optimum Use of Strengths Reduce Nurses' Time Pressure	[Wong, Alice May-Kuen] Chang Gung Mem Hosp [Yu, Wen-Pin; 鄧景宜✉] Dept Nursing

項目	出處	期刊 IF值	百分比 排名	主題	篇名	作者及發表論文單位
6	JOURNAL OF CLINICAL ONCOLOGY Volume 43 Issue 3 Published JAN 20 2025	42.1	2.48%	Oncology	Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors	[Lai, Chyong-Huey] Dept Obstet & Gynecol, Gynecol Canc Res Ctr
7	JOURNAL OF THORACIC ONCOLOGY Volume 20 Issue 1 Page 76-93 Published JAN 2025	21.1	3.03%	Oncology; Respiratory System	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial	[Yang, Cheng-Ta] Chang Gung Mem Hosp
8	LANCET Volume 405 Issue 10474 Page216-232 Published JAN 18 2025	98.4	0.60%	Medicine, General & Internal	Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo- controlled, phase 3 study	[Lin, Shi-Ming] Dept Internal Med